Characteristics of 258 patients treated with imatinib in early chronic phase
| Parameter . | Value . |
|---|---|
| Median age, y (range) | 48 (15-84) |
| Median time from diagnosis to imatinib, mo (range) | 1 (0-12) |
| Median WBC, ×109/L (range) | 26.8 (2.2-283) |
| Median hemoglobin, g/dL (range) | 12.4 (6.2-16.7) |
| Median platelets, ×109/L (range) | 365 (100-1476) |
| Median percentage of PB blasts (range) | 0 (0-12) |
| Median percentage of PB basophils (range) | 3 (0-19) |
| Median percentage of BM blasts (range) | 2 (0-14) |
| Median percentage of BM basophils (range) | 3 (0-15) |
| Splenomegaly, n (%) | 70 (27) |
| Percentage of Ph+ > 90, n (%) | 241 (93) |
| Clonal evolution, n (%) | 7 (3) |
| Dose, mg, n (%) | |
| 400 | 50 (19) |
| 800 | 208 (81) |
| Sokal risk score, n (%) | |
| Low | 165 (64) |
| Intermediate | 71 (28) |
| High | 22 (8) |
| Parameter . | Value . |
|---|---|
| Median age, y (range) | 48 (15-84) |
| Median time from diagnosis to imatinib, mo (range) | 1 (0-12) |
| Median WBC, ×109/L (range) | 26.8 (2.2-283) |
| Median hemoglobin, g/dL (range) | 12.4 (6.2-16.7) |
| Median platelets, ×109/L (range) | 365 (100-1476) |
| Median percentage of PB blasts (range) | 0 (0-12) |
| Median percentage of PB basophils (range) | 3 (0-19) |
| Median percentage of BM blasts (range) | 2 (0-14) |
| Median percentage of BM basophils (range) | 3 (0-15) |
| Splenomegaly, n (%) | 70 (27) |
| Percentage of Ph+ > 90, n (%) | 241 (93) |
| Clonal evolution, n (%) | 7 (3) |
| Dose, mg, n (%) | |
| 400 | 50 (19) |
| 800 | 208 (81) |
| Sokal risk score, n (%) | |
| Low | 165 (64) |
| Intermediate | 71 (28) |
| High | 22 (8) |
WBC indicates white blood cell; PB, peripheral blood; BM, bone marrow; and Ph, Philadelphia chromosome.